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Abstract
Mutations in the GBA gene, encoding the lysosomal hydrolase glucocerebrosidase (GCase), are the most common
known genetic risk factor for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). The present study
aims to gain more insight into changes in lysosomal activity in different brain regions of sporadic PD and DLB
patients, screened for GBA variants. Enzymatic activities of GCase, β-hexosaminidase, and cathepsin D were mea-
sured in the frontal cortex, putamen, and substantia nigra (SN) of a cohort of patients with advanced PD and DLB
as well as age-matched non-demented controls (n = 15/group) using fluorometric assays. Decreased activity of GCase
(− 21%) and of cathepsin D (− 15%) was found in the SN and frontal cortex of patients with PD and DLB compared
to controls, respectively. Population stratification was applied based on GBA genotype, showing substantially lower
GCase activity (~ − 40%) in GBA variant carriers in all regions. GCase activity was further significantly decreased in
the SN of PD and DLB patients without GBA variants in comparison to controls without GBA variants. Our results
show decreased GCase activity in brains of PD and DLB patients with and without GBA variants, most pronounced
in the SN. The results of our study confirm findings from previous studies, suggesting a role for GCase in GBA-associated as
well as sporadic PD and DLB.
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Introduction
Converging evidence from genetic, pathological, and experi-
mental studies has suggested that impairment of the
autophagy-lysosomal pathway (ALP) is a key pathological
event in the pathogenesis of Parkinson’s disease (PD) and
dementia with Lewy bodies (DLB) [1, 2]. Mutations in nu-
merous genes encoding for ALP components have been asso-
ciated with increased risk to develop PD, including
Glucosidase Beta Acid 1 (GBA) [3]. Homozygous GBA mu-
tations cause Gaucher disease (GD), and heterozygous GBA
mutations form the major genetic risk factor for PD and DLB.
The prevalence ofGBAvariants is estimated 5–10% in PD and
DLB patients and higher in certain studied populations, par-
ticularly among Ashkenazi Jews (~ 20%) [4–6]. In GD, ap-
proximately 300 different GBA mutations have been de-
scribed, many of which are also found in PD [7]. Recent
studies showed GBA mutations impact the clinical phenotype
of PD and DLB, as their presence has been associated with
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rapid eye movement sleep behavior disorder, a more rapid
disease course, earlier age of onset, and higher risk for
cognitive decline and dementia [8–11]. Moreover, a worse
outcome has been reported for pathogenic mutations, for in-
stance L444P, than for milder GBA variants such as N370S
[11–14].
GBA encodes for the lysosomal hydrolase β -
glucocerebrosidase (GCase), which catalyzes the conversion
of glucosylceramide into glucose and ceramide [5]. Decreased
protein levels and enzymatic activity of GCase were found in
affected brain regions [15–18], dried blood spots [19], fibro-
blasts [20], peripheral blood mononuclear cells [21], and CSF
[22–24] of PD patients with GBA mutations, but also in spo-
radic PD patients. Alterations in the activities of several other
lysosomal enzymes were found in brain tissue and CSF of PD
or DLB patients compared to controls, including β-
hexosaminidase (β-Hex) and cathepsin D (CathD) [22–26].
In addition, decreased protein levels have been demonstrated
for various other ALP components in the PD brain [27–30].
Together, these findings suggested that GCase dysfunction as
well as more widespread deregulation of the lysosomal system
is involved in PD and DLB pathology.
This study aims to obtain more insight into the changes in
lysosomal enzymes, including GCase, in different regions of
PD and DLB brains and their relation to the presence of dif-
ferent GBA variants. In order to do this, we measured enzy-
matic activities for GCase, CathD, and β-Hex in the frontal
cortex (FC), putamen, and substantia nigra (SN) of a clinically
and pathologically well-characterized cohort of PD and DLB
patients, as well as in age-matched non-demented controls. To
investigate whether fluctuations in enzymatic activities were
reflected at the level of mRNA, we measured expression
levels for GBA, and genes encoding CathD (CTSD),
GCase’s protein interactors lysosomal integral membrane-
protein 2 (LIMP-2) and saposin C (SapC)—which are impor-
tant determinants for GCase activity [31]—as well as selected
other components of the ALP. Our results confirm the involve-
ment of GCase in GBA-associated as well as idiopathic PD
and DLB, most pronounced in the SN, and demonstrate a
stepwise decrease in GCase activity when comparing distinc-
tive GBA genetic subgroups.
Methods
Selection of Postmortem Human Brain Tissue
Human postmortem brain tissue was collected from clinically
diagnosed and neuropathologically verified advanced PD and
DLB patients (15 per group) and 15 age-matched non-neuro-
logical control subjects from the Netherlands Brain Bank
(NBB, Amsterdam, The Netherlands; Table 1). All donors
had short postmortem delay (PMD; < 10 h), a pre-analytical
factor that can potentially impact the stability of lysosomal
enzymes [32]. In compliance with all local ethical and legal
guidelines, informed consent for brain autopsy and the use of
brain tissue and clinical information for scientific research was
given by either the donor or the next of kin. Brains were
dissected in compliance with standard operating protocols of
the Netherlands Brain Bank (www.brainbank.nl). Frozen
tissue blocks of the superior frontal cortex, putamen and SN
were collected at autopsy. Tissue blocks were pulverized using
a mixer mill (model MM400; Retsch, Haan, Germany) during
2 min at a frequency of 30 Hz. Pulverization took place in
stainless-steel grinding jars, precooled in liquid nitrogen to
prevent thawing of the tissue. The procedure was repeated,
when needed, until all tissue was pulverized. Subsequently,
tissue was stored at − 80 °C in aliquots.
Genotyping
High molecular-weight genomic DNA was extracted from
frozen cerebellum specimens using the Gentra Puregene
Tissue Kit (Qiagene, Hilden, Germany). The genomic region
encompassingGBA open reading framewas amplified in large
fragments in order to avoid amplification of the neighboring
GBAP pseudogene. Subsequently, we Sanger sequencedGBA
in 43 samples, as for 2 samples (1 control, 1 DLB patient), no
brain tissue was available.We report variants if they are of
coding effect or within 20 bp from the intron-exon
boundaries, and if their minor allele frequency (MAF)
is lower than 1% in Exome Aggregatium Consortium
browser (ExAC, http://exac.broadinstitute.org/). Variants
nomenclature is assigned according to NM_000157.3
transcript, consisting of 11 exons and encoding for a total of
536 amino acids. We also report common nomenclature
attributed to GBA variants (between brackets), in which the
amino acid count does not include the initial 39 amino acids
corresponding to the residue signal peptide. We investigated
the effect on splicing of GBA c.762-18T>A variant according
to five splicing prediction tools (SpliceSiteFinder-like,
MaxEntScan, NNSPLICE, GeneSplicer, and Human
Splicing Finder) integrated in Alamut Visual version 4.2
(Interactive Biosoftware, Rouen, France).
Enzyme Activity Assays
Pulverized tissue (approximately 50 mg) was lysed in a
50 mM sodium/phosphate (Na/P), 150 mM NaCl buffer,
pH 7.0 and homogenized using a homogenizer (Ultra-turrax,
model T10B; IKA, Wilmington, NC, USA), after which
0.1% of tergitol-typenonyl phenoxypolyethoxylethanol
40 (Igepal CA630; Sigma-Aldrich, Saint Louis, MO,
USA) was added. Samples were ultra-sonicated
(Sonopuls, model: UW3100; Bandelin, Berlin, Germany),
kept on ice for 30 min, and subsequently centrifuged at a
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speed of 15,000×g for 10 min in a bench centrifuge
(model 5415D; Eppendorf, Hamburg, Germany).
Fluorometric enzyme activity assays (EAAs) for
GCase, β-Hex, and CathD were performed in accor-
dance with the protocols previously described [16, 25].
All EAAs were performed in triplicate. Mean intra-assay
coefficients of variation (CV) were lower than 5% for
all enzymes, with a maximum CV of 8.5%. Enzymatic
activities were normalized for total protein content of
the samples to obtain the specific activity. Total protein
concentration in the samples was determined according
to the method described by Bradford [33].
RNA Extraction and Quantitative PCR
To determine whether fluctuations in enzymatic activities
were reflected at the level of mRNA, we have measured the
expression levels for different ALP-related genes using quan-
titative PCR (qPCR). Experiments were performed on pulver-
ized FC and SN tissue, but not on putamen as not enough
material was left. Apart from GBA, mRNA expression levels
were measured for the genes that encode CathD and GCase’s
protein interactors LIMP-2 (SCARB2) and saposin C (PSAP)
[31]. Finally, genes encoding lysosomal membrane-associated
receptors (LAMP-1; LAMP-2) and autophagy (TFEB) were
measured as more general markers for the ALP. RNA extrac-
tion was performed as previously described, using a Trizol/
chloroform protocol [34]. The RNA integrity number (RIN)
was determined using an Agilent TM 2100 Bioanalyzer and
an RNA 6000 Nano LabChip Kit (Agilent Technologies, Palo
Alto, CA, USA). We applied an RIN value of 5.0 as
threshold for inclusion for the qPCR analysis. Consequently, a
smaller subset of 29 samples was included for the FC (11
controls/10 PD/ 8 DLB) and 27 for the SN (10 controls/9
PD/8 DLB). cDNA synthesis was done using the High-
Capacity cDNA Reverse Transcription Kit (Art. No.
4368814; ThermoFischer, Waltham, MA, USA), and cDNA
was stored at − 20 °C until use. For all genes of interest,
intron-spanning Taqman assays were designed (Table S1).
Primers were synthesized by Eurogentec (Luik, Belgium).
Taqman probes were selected from the Human Universal
Probe Library (UPL; Roche Applied Science, Indianapolis,
IN, USA). For normalization, the housekeeping genes m-
RIP, OAZ-1, and POL2RF were selected using geNorm
software from a subset of candidate housekeeping genes
[35]. Standard curves were generated for each assay
run. The relative expression ratio of each target gene
was calculated using the efficiency-corrected delta-delta
Cq method [34, 36]. All assays were performed in duplicate
(mean CV = 5.4%).
Statistics
Hierarchical clustering analysis was done using R soft-
ware (Version 3.2.5, R Foundation for Statistical
Computing, Vienna, Austria) [37], to compare lysosomal
enzyme activities across different brain areas. Further
statistical analyses were performed using SPSS package
version 20.0 (Statistical Product and Service Solutions).
As enzyme activities between brain regions were corre-
lated within subjects, general linear models for mixed
effects were used to test for differences between PD
and DLB patients with controls, in which contribution
of individual patient groups per brain region were fur-
ther studied. In other comparisons, ANCOVA analyses
were applied. In all models, age was included as a co-
variate. For the qPCR data, the RIN value was included
as weighted least squares weight to the models. A p
value < 0.05 was considered significant in all analyses.
All reported p values were corrected for multiple com-
parisons: multiple comparisons were taken into account
in the general linear model for mixed effects, while
Bonferroni post hoc tests were applied in the univariate
models. Graphs and figures were generated using R
software and GraphPad (Version 7.0, Prism, La Jolla,
CA, USA) and composed in Adobe Photoshop (version
CS6, Adobe Systems Incorporated, San Jose, CA).
Table 1 Cohort demographics.
*p < 0.05 (Pearson chi-square test) Controls (N = 15) PD (N = 15) DLB (N = 15) p value
Age of death (years ± SD) 77 ± 6 77 ± 5 77 ± 5 0.67
Sex (M/F) 4/11 11/4 10/5 0.02*
Postmortem delay (hours ± SD) 6.3 ± 1.7 6.0 ± 1.8 5.2 ± 1.2 0.47
Braak Lewy Body Score 0–1 (14/1) 4–6 (3/5/7) 4–6 (3/3/9) < 0.01*
Braak score for Neurofibrillary Tangles 0–2 (2/6/7) 0–3 (2/9/2/2) 0–3 (1/8/5/1) 0.46
CERAD Amyloid Plaque Score 0-B (4/7/4) O-C (7/5/2/1) O-C (3/3/8/1) 0.21
Disease duration (years ± SD) – 15 ± 7 6 ± 3 < 0.01*
No. of donors with GBA risk factors 2 3 4 –
No. of donors with pathogenic GBAvariants 0 3 0 –
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Results
Lysosomal Enzyme Activities
Lysosomal enzyme activities across samples revealed differ-
ences between brain regions (Fig. 1a). GCase activity was
higher in the FC compared to the other regions, while CathD
and β-Hex activities were highest in the putamen. Activities
of different lysosomal enzymes were sometimes correlated
within a brain region, but not with postmortem delay
(Fig. 1b–d). GCase activity was significantly decreased
in the SN of PD and DLB patients compared to controls
(− 21%; p = 0.02), while this effect was not significant in other
studied brain regions (Fig. 2b, d). Post hoc analyses revealed
that GCase was particularly decreased in the SN of PD pa-
tients compared to controls (− 22%; p = 0.04), with a similar
Fig. 1 Lysosomal enzymatic activities in different regions of the human
postmortem brain. a Cluster analysis of average enzymatic activities
across patients for GCase, β-Hex, and CathD in the different studied
regions reveals that GCase activity was highest in the frontal cortex,
while CathD and β-Hex activities were higher in the putamen
compared to the other studied regions. b, c, and d Correlation matrices
for lysosomal enzymatic activities and PMD for frontal cortex (b),
putamen (c), and SN (d). High correlations were sometimes observed
between activities of different lysosomal enzymes, but not with PMD.
Values represent Spearman’s correlation coefficients. *p < 0.05;
**p < 0.01; ***p < 0.001
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trend in DLB patients (− 20%; p = 0.06). No differences in
GCase activity were observed between PD and DLB patient
groups in any of the studied brain regions. For CathD, a sig-
nificant decrease in enzymatic activity was found in the FC of
PD and DLB patients compared to controls (− 15%; p = 0.05;
Fig. 2c). This effect was most pronounced in DLB patients (−
18%; p = 0.04) while a similar trend did not reach significance
in PD patients (− 12%; p = 0.16). For the activity ofβ-Hex, no
between-group differences were observed in any of the mea-
sured brain regions (Fig. 2a).
Gene Expression
To examine whether changes in enzyme activity were
reflected at the mRNA level, gene expression was assessed
for GBA and CTSD. In addition, mRNA expression levels
were measured for genes encoding the GCase protein
interactors LIMP-2 (SCARB2) and saposin C (PSAP), which
are important determinants for GCase activity [31]. Finally,
gene expression levels were measured for more general
markers associated with lysosomes (LAMP-1; LAMP-2) or
the ALP (TFEB; Fig. 3g). GBA and CTSD expression were
not correlated with GCase or CathD activity in both SN and
FC (Fig. S1). However, strong correlations between mRNA
expression levels were found between certain ALP genes, for
instance between GBA and SCARB2 (Fig. 3a). Normalized
mRNA expression levels for all measured genes showed sub-
stantial variability within groups. Still, decreased normalized
GBAmRNA expression levels were observed in the SN of PD
and DLB patients compared to controls (− 13%; p = 0.04;
Fig. 3a, g). A similar pattern could be observed in the FC,
although differences were not significant (− 16%; p = 0.17).
No significant differences in the mRNA expression levels
were found for CTSD or any of the other measured ALP-
related genes in either FC or the SN (Fig. 3c, f).
GBA Screening
According to above-mentioned criteria, sixGBAvariants were
detected in a total of 12 out of 43 tested specimens, and
Fig. 2 Lysosomal enzyme activities in the brain of PD and DLB patients
compared to controls. Group comparison of measured specific activities
for β-Hex (a), GCase (b), and CathD (c) expressed in pmol/min/mg of
proteins. Graphs show the average specific activity and standard
deviation for non-demented controls (blue), PD patients (green), and
DLB patients (blue). d. Overview of mean enzyme activities ± standard
deviations. The p value indicates the between-group difference per brain
region. GCase activity was significantly decreased in the SN of PD
patients compared to controls, while lower CathD activity was found in
the frontal cortex of DLB patients compared to controls *p < 0.05
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specifically in 6 PD patients, 4 DLB patients and 2 non-
demented controls (Table 1). Based on previous literature
as well as on the predicted effect on GCase functioning,
a distinction was made between putative pathogenic
variants—that are causative for GD—and variants that
are risk factors for PD. We identified GBA c.535G>C
p.Asp179His (p.Asp140His) and GBA c.1448T>C
p.Leu483Pro (p.Leu444Pro) variants in heterozygous state in
Fig. 3 mRNA expression levels for GBA, CTSD, and other ALP
components. Correlation matrices showing association between mRNA
expression levels of GBA and genes encoding CTSD, GCase’s protein
interactors LIMP-2 (SCARB2) and saposin C (PSAP), and the
lysosomal membrane-associated protein LAMP-1 in the frontal cortex
(a) and SN (b). Normalized mRNA expression levels for GBA (c),
CTSD (d), and SCARB2 (e) in PD (green) and DLB (red) patients as
well as non-demented controls (blue). Expression levels are expressed
as percentage of the average expression level of non-demented controls.
f Schematic outline of the interplay between the measured gene products.
LIMP-2 functions as a transporter molecule for GCase from the
endoplasmatic reticulum, while the interaction of GCase with SapC is
essential for its proper function [31]. LAMP-1 and LAMP-2a are
lysosome-associated membrane proteins, while transcription factor EB
(TFEB) is the master regulator of biogenesis and function of lysosomes,
by activating transcription of autophagy-related genes (ATGs). *p < 0.05;
**p < 0.01; ***p < 0.001
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ID-24 and ID-26 PD donors, respectively. In the context of
recessive inheritance, both variants have been associated with
GD and with PD if carried in heterozygous state [38]. In ID-18
(PD), we identified a GBA c.1073C>T p.Pro358Leu
(p.Pro319Leu) variant, which has been reported before in a
Dutch patient with GD type 1 [39]. As this variant affects an
evolutionary-conserved amino acid, it is likely pathogenic [40].
Apart from these GD-associated pathogenic mutations, we
detected variants in our cohort for which the association with
GD is less clear. First, we detected heterozygous GBA
c.1093G>A p.Glu365Lys (p.Glu326Lys) and GBA
c.1223C>T p.Thr408Met (p.Thr369Met) variants in eight (3
PD and 3 DLB patients, 2 controls) and two (1 PD and 1 DLB
patients) brain specimens, respectively. Both of these variants
are not causative for GD in homozygous carriers, although
they may modify GCase activity and GD phenotype [41,
42]. In particular, p.Glu326Lys has been established as risk
factor for PD, as it is the most prevalent PD-associated GBA
mutation, which was demonstrated in a large meta-analysis
combining data from different genome-wide association stud-
ies [43]. Although the association of p.Thr369Met variants
with PD is more controversial, accumulating evidence sug-
gests that this variant may be risk factor with a minor effect
[41]. Therefore, both p.Glu326Lys and p.Thr369Met were
considered as GBA risk factors in further analyses [6, 10,
41]. Finally, we found GBA c.762-18T>Avariant in homozy-
gous state in ID-16 PD patient’s brain. Yet, this variant is not
reported to be associated with GD nor PD. Out of 5 addressed
splicing prediction tools, only the Human Splicing Finder pre-
diction software predicts that the alternative nucleotide intro-
duces a weaker acceptor site, but without affecting the effi-
ciency of the default one. Based on these observations, we
have considered the c.762-18T>A as potential PD risk factor
rather than pathogenic variant in our analysis. Of note, for all
these detectedGBA PD risk factors, althoughMAFs are lower
than 1% in the ExAc database (p.Glu326Lys, 0.98%;
p.Thr369Met, 0.66%; c.762-18T>A, 0.79%), their occurrence
in the Netherlands is higher than 1%, as shown by the GoNL
database (p.Glu326Lys, 2.3%; p.Thr369Met, 1.1%; c.762-
18T>A, 1.2%) [44].
One PD donor (ID-24) was found to carry three GBA alter-
ations, namely, c.535G>C p.Asp179His (p.Asp140His),
c.1093G>A p.Glu365Lys (p.Glu326Lys), and c.1223C>T
p.Thr408Met (p.Thr369Met) variants. Unfortunately, the
phase of these variants (cis or trans) could not be established
as relatives of the carrier were not available for testing. There
are examples in the literature in which multiple GBA variants
are located on the same chromosome as the result of complex
genomic rearrangements occurring between the GBA gene
and the GBAP pseudogene [7], which cannot be ruled out in
this case. Moreover, the co-occurrence of p.Asp140His plus
p.Glu365Lys variants on complex alleles has been reported
repeatedly [12, 45, 46]. Of interest, although this patient
possibly met the biochemical and genetic criteria for being
diagnosed with GD [47], clinically and pathologically she
was referred as affected by PD.
In our study design, it was not possible to differentiate PD/
DLB patients with GBA variants (PD/DLB+GBA) from PD/
DLB-GBA patients based on clinical symptoms, mainly be-
cause of the limited sample size. However, for all GBA variant
carriers in our study substantial cognitive symptoms and other
non-motor symptoms were reported during the disease course,
including visual hallucinations. An overview of prominent clin-
ical features of the PD and DLB patients with GBA variants in
our study is provided in Table S3. All cases with GBA variants
showed widespread Lewy Body pathology at autopsy, with
Braak α-synuclein stages similar to non-carriers in our study.
Population Stratification Based on GBA Variants
GCase activity was substantially lower in PD/DLB+GBA pa-
tients in comparison to controls without GBA variants
(p < 0.0001). This effect was present in all studied brain re-
gions (Fig. 4a–e). Moreover, GCase enzymatic activity was
significantly decreased in the group of PD/DLB+GBA pa-
tients compared to PD/DLB-GBA patients, confirming that
the presence of GBA variants was a major determinant for
GCase activity in our cohort. However, the group of PD/
DLB-GBA patient showed significantly decreased GCase ac-
tivity compared to control subjects without GBA variants in
the SN (19%; p = 0.04), but to lesser extent in other brain
regions (Fig. 4a, b). Similar to GCase activity, CathD activity
was substantially decreased in the FC of PD/DLB+GBA pa-
tients compared to controls without GBA variants (− 31%;
p < 0.01; Fig. 4c). However, CathD activity was not signifi-
cantly altered in the other brain regions. For β-Hex, no differ-
ences in enzymatic activity were observed between PD/DLB+
GBA, PD/DLB-GBA patients, and controls in any of the stud-
ied brain regions (Fig. 4d). The differences in GCase activity
between PD/DLB+GBA, PD/DLB-GBA patients, and controls
were not reflected by alterations on the mRNA level in either
FC or SN (Fig. 4f).
Discussion
The present study provides a comprehensive measurement of
enzymatic activities as well as mRNA expression levels for
GCase and other ALP components in selectively vulnerable
regions of patients with advanced PD patients and DLB. We
found that GCase activity is decreased in postmortem brains
of PD and DLB patients with and without GBA variants com-
pared to age-matched controls. Thereby, we confirm findings
of previous studies in brain tissue from an independent cohort
of clinically and pathologically well-characterized donors
with PD andDLBwith short PMD.Our study further provides
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Fig. 4 Population stratification based on GBA genotype. Specific
enzymatic activities for GCase (a), β-Hex (c), and CathD (d) for
non-demented controls without GBA variants (blue) and with GBA
risk factors (orange), for PD and DLB patients without GBA
variants (green), with GBA risk factors (red), and with
pathogenic GBA variants (purple). b Measured GCase activities
in the SN per GBA variant for controls (blue), PD patients
(green), and DLB patients (red). d Overview of mean enzyme
activities ± standard deviations in different GBA genetic
subgroups. p values indicate the between-group difference per
brain region. e GBA mRNA expression levels for controls, PD
and DLB patients without GBA variants, with GBA risk factors,
and pathogenic GBA variants. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001
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insight in the relation between brain GCase activity and the
presence of different GBA variants. In particular, population
stratification based on GBA genotype showed a genotype-
dependent decrease in GCase activity (Fig. 4). Finally, we
observed decreased CathD activity in the FC of PD and
DLB patients compared to controls, particularly in patients
carrying GBA mutations.
As reported in previous studies, we find the most pro-
nounced effects in the SN, a region associated with α-
synuclein pathology and other biochemical abnormalities, in-
cluding mitochondrial dysfunction, oxidative stress, and neu-
rodegeneration [15, 16]. A contribution of dopaminergic cell-
death in the SN to the reduction of GCase activity in this
region cannot be excluded in our study. However, we did
not observe differences in total protein content—for which
we corrected enzymatic activities—or in other measured com-
ponents (for instance β-Hex activity) in the SN of PD and
DLB patients compared to controls. Moreover, a previous
study did not detect changes in GCase activity in brain regions
with massive neurodegeneration, such as the amygdala of do-
nors with Alzheimer’s disease [15].
We found a significant 19% decrease of GCase activity in
the SN of patients without GBA mutation compared to con-
trols, which is in line with the slightly higher (33%) [15] or
lower (12%) [16] differences that were previously reported in
this brain region. However, in the first study, a possible con-
tribution ofGBA variants in the group of sporadic PD patients
cannot be ruled out as no genetic screening was reported for
this group of donors [15]. Genotyping of our cohort revealed a
markedly high rate of GBA variants, with 6 carriers out of 15
screened PD donors, 4/14 DLB donors, and 2/14 screened
controls. Two previously defined pathogenic variants
(Asp140His and p.Leu444Pro) were detected, while one pos-
sibly pathogenic missense variant (p.Pro319Leu) was found.
The presence ofGBAvariants resulted in a substantially lower
GCase activity in all studied brain regions (~ − 40%), most
pronounced in the SN, where the PD/DLB+GBA group
showed no overlap with controls (Fig. 4b).
GCase activities were lowest in donors with pathogenic
GBA variants. Although sample size for different genetic
GBA subgroups—particularly, the number of donors with
pathogenic GBA variants—was small, our data indicates a
stepwise decrease in GCase activity in different GBA genetic
subgroups. Interestingly, a similar Bdose-effect^ of GBA vari-
ants in PD has been suggested in recent clinical and genetic
studies, in which differential effects of mild and severe GBA
variants on PD clinical phenotype were reported. Severe GBA
variants were associated with more progressive forms of PD
[9, 11–13], and with higher genetic risk to develop PD [14].
Insight into the effects of different GBA variants on GCase
activity in the brain can be important for patient selection
and therapeutic efficacy for novel therapies that aim to in-
crease GCase enzyme activity as disease-modifying therapy
in PD/DLB, for instance using small molecule non-inhibitory
chaperones [48].
The lowest GCase activity was detected in PD donor ID-24
who carried three GBA variants, whose phases (cis or trans)
could not be established. Therefore, it is not clear whether
these three variants contribute to the lower enzymatic activity
in an independent manner, with the p.Asp140His variant act-
ing as driving factor, or if they act in a synergic fashion. The
extremely low GCase enzymatic activity prompts us to spec-
ulate that bothGBA alleles are altered, with two variants being
in cis and the remaining one in trans. In particular, a combi-
nation of p.Asp140His plus p.Glu365Lys variants at one allele
has been reported in several studies [12, 45, 46]. Of interest is
the fact that this patient, despite of very low GCase activities,
was diagnosed with PD and not with GD during her life.
To investigate whether changes in enzymatic activity were
reflected at the level of mRNA, we measured expression
levels of GBA and CTSD. In addition, we measured expres-
sion levels for genes encoding GCase’s protein interactors
LIMP-2 and SapC—which are proposed to be important de-
terminants for GCase activity [31], to explore their interrela-
tion. No correlation was found between GBA and CTSD
mRNA expression with GCase or CathD activity in our data,
while the systematic decrease in GCase activity in different
pathological and genetic GBA subgroups was not observed at
the mRNA level. The lack of association between mRNA
levels and GCase enzymatic activity was not unexpected, as
it has been reported before in studies on GD [7], and indicates
that GCase activity is not simply a reflection of a GBA gene
expression but also driven by other factors. In that aspect, it is
interesting that we observed strong correlations between GBA
and genes encoding its posttranslational regulators LIMP-2
and SapC, indicating an interrelation of these components at
a transcriptional level.
Gene expression data showed large variability in patients
and controls. This variability may be partially explained by
differences in tissue composition. In particular, the content of
cellular components in diseased tissue can be changed as a
result of inflammatory and neurodegenerative processes.
Despite of this variability, still, a trend for decreased GBA
mRNA expression levels was observed in the SN of PD and
DLB patients. Reduced GBA expression in the SN has previ-
ously been reported [16], while another study reported a trend
for decreased GBA mRNA expression in the anterior cingulate
cortex [17]. In other regions, including putamen [15] and oc-
cipital cortex [17], no evidence of reducedGBAmRNA expres-
sion was found. Interestingly, the results after population strat-
ification showed that reduced GBA expression was not associ-
ated with the presence of GBA variants. Taken together, we
conclude that lower GCase activities do not correspond with
lower mRNA levels, while a role for alteredGBAmRNA levels
in sporadic PD and DLB cannot be excluded. However, at this
point, the relevance of this latter observation is not clear.
Mol Neurobiol
We did not find differences in β-Hex activities between
PD and DLB patients compared to controls. A role for β-
Hex in PD pathology has been suggested, as patients af-
fected by GM2 gangliosidosis, which results from reduced
β-Hex activity, can manifest with parkinsonism [49–51].
Further, a role of β-Hex in PD pathogenesis is supported
by animal studies showing that mice lacking β-Hex
showed α-synuclein-positive neuronal inclusions at
4 months of age [52]. In biomarker studies, it was reported
that CSF β-Hex enzyme activity is altered in PD patients
compared to age-matched neurological controls [22, 23].
However, no difference in β-Hex activity was detected in
brain tissue of PD and DLB patients compared to controls,
in our and also other studies [15, 16, 24–26]. Together, the
evidence for a role of β-Hex in sporadic PD is currently
limited.
We observed decreased CathD activity in the FC of
DLB patients compared to controls, while a similar non-
significant effect was observed in PD patients. Of inter-
est, CathD activity was particularly decreased in patients
with GBA variants. A role for CathD has been proposed
in different neurodegenerative diseases [53], including
Alzheimer’s disease, Huntington’s disease, and PD
[54–57]. Our results are in line with a previous study,
which also showed lower CathD activity in the FC of
patients with PD and DLB [28], while reduced expres-
sion levels of CathD have also been reported in the SN
of PD patients [27]. CathD is a lysosomal protease involved in
the posttranslational cleavage of prosaposin (encoded by
PSAP), leading to the production of saposin C, a GCase acti-
vator [31, 58]. Thus, interestingly, although we did not find
changes in the mRNA expression of PSAP, the activity of the
enzyme responsible for its posttranslational regulation was
altered.
The within-subject design of our study allowed to
demonstrate the differential regulation of lysosomal en-
zymatic activity in different brain regions, as has been
suggested previously in the literature [16]. However, in
contrast to this study [16], enzyme activities were not
generally higher in the SN. Rather, this effect seems to
depend on the specific lysosomal enzyme, as CathD
activity was significantly higher in the putamen than
in SN and FC. A systematic mapping of lysosomal en-
zyme gene/protein expression and activities in the brain
could provide more insight into the differential regula-
tion of lysosomal enzymes between brain regions, and
may allow better understanding of region-specific effects
of lysosomal proteins.
In conclusion, our results show decreased GCase activ-
ity in the brain of PD and DLB patients with and without
GBA variants. GCase activities in brain tissue were related
to the presence as well as the pathogenicity of GBA var-
iants. The results of our study confirm findings from
previous studies, and provide important insights into the
role of GCase in GBA-associated as well as sporadic PD
and DLB.
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